~~<i id='91F9DD748F'><strike id='91F9DD748F'><tt id='91F9DD748F'><pre id='91F9DD748F'></pre></tt></strike></i>~~

Home» leisure time» leisure time

leisure time

author：hotspot 2025-10-02 05:04:58 Page View：32738

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Buoyed by wins on obesity, Novo Nordisk eyes heart disease
Next article： At least 13 dead in Texas as scorching temps continue

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

New Alzheimer's drugs heat up race for early detection blood tests

MarionBerard/AFP/GettyImagesWiththeadventofdisease-modifyingAlzheimer’sdrugs,everyoneintheworldofAlz

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

AdobePHILADELPHIA—NovoNordisk,whichhasdominatedthediabetesandobesitymarketswithitsblockbusterdrugsOz